Cited by 826Atrial Fibrillation Management and OutcomesBlood Pressure and Hypertension StudiesCardiac electrophysiology and arrhythmias

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol

Open access

Wachtell, Kristian, Lehto, Mika, Gerdts, Eva, Olsen, Michael H., Hornestam, Björn, Dahlöf, Björn, Ibsen, Hans, Julius, Stevo, Kjeldsen, Sverre E., Lindholm, Lars H., Nieminen, Markku S., Devereux, Richard B.·2005·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2004.10.068

Open this paper in CoChat — free account Open PDF

Abstract

Objectives This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF).Background It is unknown whether angiotensin II receptor blockade is better than beta-blockade in preventing new-onset AF.Methods In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy. Electrocardiograms were Minnesota coded centrally, and 8,851 patients without AF by electrocardiogram or history, who were thus at risk of developing AF, were followed for 4.8 +/- 1.0 years.Results New-onset AF occurred in 150 patients randomized to losartan versus 221 to atenolol (6.8 vs. 10.1 per 1,000 person-years; relative risk 0.67, 95% confidence interval [CI] 0.55 to 0.83, p < 0.001) despite similar blood pressure reduction. Patients receiving losartan tended to stay in sinus rhythm longer (1,809 +/- 225 vs. 1,709 +/- 254 days from baseline, p = 0.057) than those receiving atenolol. Moreover, patients with new-onset AF had two-, three- and fivefold increased rates, respectively, of cardiovascular events, stroke, and hospitalization for heart failure. There were fewer composite end points (n = 31 vs. 51, hazard ratio = 0.60, 95% CI 0.38 to 0.94, p = 0.03) and strokes (n = 19 vs. 38, hazard ratio = 0.49, 95% CI 0.29 to 0.86, p = 0.01) in patients who developed new-onset AF in the losartan compared to the atenolol treatment arm of the study. Furthermore, Cox regression analysis showed that losartan (21% risk reduction) and new-onset AF both independently predicted stroke even when adjusting for traditional risk factors.Conclusions Our novel finding is that new-onset AF and associated stroke were significantly reduced by losartan- compared to atenolol-based antihypertensive treatment with similar blood pressure reduction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2004.10.068

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citation
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study
Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. V. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01236-6 · Cited by 1,562
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary
Fuster, V., Rydén, L., ASINGER, R. W., Cannom, D. S., Crijns, H. J. G. M., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Lévy, S., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01587-x · Cited by 1,362
Left Atrial Size and the Risk of Stroke and Death
Benjamin, E. J., D’Agostino, R. B., Belanger, A. J., Wolf, P. A., & Levy, D. A. (1995) · Circulation · doi:10.1161/01.cir.92.4.835 · Cited by 1,058
Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing–Induced Congestive Heart Failure
Li, D., Shinagawa, K., Pang, L., Leung, T. K., Cardin, S., Wang, Z., & Nattel, S. (2001) · Circulation · doi:10.1161/hc4601.099402 · Cited by 702
Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study
Madrid, A. H., Bueno, M. G., Rebollo, J. M. G., Marín, I., Peña, G., Bernal, E., Rodriguez, A., Cano, L., Cano, J. M., Cabeza, P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000022665.18619.83 · Cited by 685
Trandolapril Reduces the Incidence of Atrial Fibrillation After Acute Myocardial Infarction in Patients With Left Ventricular Dysfunction
Pedersen, O. D., Bagger, H., Køber, L., & Torp-Pedersen, C. T. (1999) · Circulation · doi:10.1161/01.cir.100.4.376 · Cited by 656
Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction
Vermès, E., Tardif, J., Bourassa, M. G., Racine, N., Lévesque, S., White, M., Guerra, P. G., & Ducharme, A. (2003) · Circulation · doi:10.1161/01.cir.0000072793.81076.d4 · Cited by 575
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation
Kumagai, K., Nakashima, H., Urata, H., Gondo, N., Arakawa, K., & Saku, K. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00464-9 · Cited by 472

Flagged first, then by citations

Show all 27 references

Sorted by citations

Items 701–800 of 819

Bluthochdruck und Herzrhythmusstörungen - eine gefährliche Kombination
Strohmer, B. (2009) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Characterization and processing of atrial fibrillation episodes by convolutive blind source separation algorithms and nonlinear analysis of spectral features
Vayá, C. (2010) · doi:10.4995/thesis/10251/8416
Treatment of High-Risk Hypertensive Patients
Ruilope, L. M., Segura, J., Tocci, G., & Volpe, M. (2006) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/00151642-200613010-00003
Fármacos para control de la frecuencia ventricular y fármacos no-antiarrítmicos en fibrilación auricular
Vicens Martí, C., & Markarian, L. (2007) · Revista Portuguesa de Pneumologia
Comparison of Angiotensin Converting Enzyme Inhibitors and Beta Blockers in Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion Elektriksel Kardiyoversiyon Sonrasında Atriyal
GÜRLEK, A. T. (2007) · Ankara Üniversitesi Tıp Fakültesi Mecmuası · doi:10.1501/tipfak_0000000570
Le médicament du mois, EXFORGE® : première association d'un antagoniste calcique (bésylate d’amlodipine) et d'un inhibiteur des récepteurs de l'angiotensine II (valsartan)
Krzesinski, J.-M., & Scheen, A. J. (2007) · RMLG. Revue médicale de Liège
Ambulatory Blood Pressure Adds to Explaining Benefits of AT‐1 Receptor Blockade in the Treatment of Left Ventricular Hypertrophy
Kjeldsen, S. E., Oparil, S., Narkiewicz, K., & Hedner, T. (2007) · Blood Pressure · doi:10.1080/08037050701797263
Self-citation
Does GISSI-AF change the concept of using RAS inhibitors in the primary prevention of atrial fibrillation in hypertensive patients?
Kjeldsen, S. E., Oparil, S., Hedner, T., & Narkiewicz, K. (2009) · Blood Pressure · doi:10.1080/08037050903040777
Self-citation
Reducing the Risk of Recurrences after Pulmonary Vein Isolation: What Is the Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers?
Steinberg, J. S., & Garikipati, N. V. (2010) · Cardiology · doi:10.1159/000320069
Is it time to review the treatment strategies in hypertension guidelines?
Meredith, P. (2009) · Hipertensión y Riesgo Vascular · doi:10.1016/s1889-1837(09)72175-0
Clinical benefits from combination therapy in the treatment of hypertension
Fogari, R., & Zoppi, A. (2010) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2009.03.002
The beneficial effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors on atrial electrical remodeling in patients with essential hypertension
Celık, T., Iyısoy, A., Kardeşoğlu, E., & Işık, E. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.07.140
La regresión de la hipertrofia ventricular izquierda disminuye la incidencia de fibrilación auricular en pacientes hipertensos
de la Figuera, M. (2007) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(07)71599-2
Present and Prospective Clinical Therapeutic Options for the Elderly Patient with Hypertension
Lechleitner, M., & Hoppichler, F. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s2110
Quelles précautions chez un patient en arythmie complète par fibrillation auriculaire avant une anesthésie ?
Piriou, V., Mismetti, P., Steib, A., Chevallier, P., & Marret, E. (2007) · Le Praticien en Anesthésie Réanimation · doi:10.1016/s1279-7960(07)91479-5
What Should We Expect from the Next Guidelines on Hypertension?
Volpe, M. (2005) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/00151642-200512040-00001
Antagonistas de los receptores de la angiotensina y protección frente al desarrollo de la cardiopatía hipertensiva
Martínez, V. B., & Pernas, D. N. (2007) · Hipertensión · doi:10.1016/s0212-8241(07)75764-x
Hypertension artérielle et troubles du rythme
Galinier, M., Pathak, A., Lairez, O., & Dumonteil, N. (2007) · EMC - Cardiologie · doi:10.1016/s1166-4568(07)45131-2
Papel actual de los antagonistas de los receptores de la angiotensina II y de sus combinaciones en el tratamiento de la hipertensión arterial
Armario, P., del Rey, R. H., & Oliveras, A. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2009.04.001
Alteraciones estructurales precoces asociadas al remodelado eléctrico de la fibrilación auricular en un modelo canino de estimulación auricular sostenida a altas frecuencias. Efecto protector del Irbesartán
Sánchez‐Quintana, D., Cabrera, J. Á., Climent, V. E., Murillo, M., Castilla, C., & Pérez, P.-P. (2009) · Revista Iberoamericana de Arritmología · doi:10.5031/v1i1.ria1066
Diagnóstico y manejo de las taquicardias supraventriculares: flutter y fibrilación auricular
René Asenjo, G. (2010) · Medwave · doi:10.5867/medwave.2010.02.4405
Restoring Sinus Rhythm: A Novel Antihypertensive Therapy?
Raviele, A. (2012) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2012.02330.x
Black Pearl in the LIFE Study: Angiotensin-II Receptor Blockade on Atrial Fibrillation for Future Personalized Medicine
Ogimoto, A., Shigematsu, Y., Hara, Y., Ohtsuka, T., Miki, T., & Higaki, J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.035
Gaps in the ARB Knowledge Base: Are ARBs Effective Anti–Atrial Fibrillation Agents?
Kowey, P. R. (2009) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2009.00214.x
Fibrillation atriale au premier mois d’un infarctus du myocarde avec sus-décalage ST
Halalchi, M., & Blangy, H. (2011) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2010.12.027
¿Es posible prevenir la fibrilacion auricular y sus complicaciones?
Marianella, S. R. (2012) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(12)70375-9
2007 Update Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women:
Taubert, K. A., Todd, B. A., Urbina, E. M., WENGER, N. K., Sherif, K., Smith, S. C., Sopko, G. S., Steinhorn, R. H., Neil, J. M., Öz, M. C., et al. (2007)
Studies of risks associated with atrial fibrillation
Olsson, L. (2010) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Perspectivas futuras del tratamiento con antagonistas de los recepetores de la angiotensina
de la Sierra, A. (2007) · Hipertensión · doi:10.1016/s0212-8241(07)75768-7
Benefits of angiotensin-II receptor blockers. Are we going beyond blood pressure control?
Volpe, M., & Tocci, G. (2006)
Heart Failure, Atrial Fibrillation, and Diabetes Mellitus
Aleksova, A., Perkan, A., & Sinagra, G. (2007) · Springer eBooks · doi:10.1007/978-88-470-0558-7_5
Trattamento farmacologico non antiaritmico della fibrillazione atriale: il punto sui farmaci ad azione sul sistema renina-angiotensina
Durin, O., Pedrinazzi, C., & Inama, G. (2008) · Giornale italiano di cardiologia · doi:10.1714/675.7856
Ablation von paroxysmalem und persistierendem Vorhofflimmern mit der Doppel-Lasso-Technik
Tilz, R. R., Ouyang, F. O., Chun, J., Schmidt, B., Satomi, K., Zerm, T., Ernst, S., Köktürk, B., Köster, I., & Antz, M. (2007) · Journal für Kardiologie (Krause & Pachernegg GmbH)
European Society of Hypertension Scientific Newsletter: Update on Hypertension Management 2009; 10: No. 42* Hypertonie und Vorhofflimmern mit Schwerpunkt auf Prävention Hypertension and Atrial Fibrillation with Emphasis on Prevention
Kjeldsen, S. E., Aksnes, T. A., & Schmieder, R. E. (2010) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Self-citation
Importancia de la prevención de la fibrilación auricular en el paciente hipertenso
Suárez, C. R., Tomás, J. P., Donaire, J. A. G., & de la Morena, J. S. (2007) · Hipertensión y Riesgo Vascular · doi:10.1016/s1889-1837(07)71691-4
Atrial Fibrillation and Heart Failure Syndromes
Williams, L. K., Lip, G. Y. H., & MacFadyen, R. J. (2010) · Springer eBooks · doi:10.1007/978-1-84996-153-0_16
Bewertung des Langzeitverlaufs nach Katheterablation von intermittierendem und persistierendem Vorhofflimmern mittels Tele-EKG: Prognostische und therapeutische Implikationen.
Brandstrup, B. (2008)
Rhythm control strategies for symptomatic atrial fibrillation
Hemels, M. E. W. (2007) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Renin angiotensin aldosterone system blockade in practice: A Clinical Perspective
Misra, V. K., & Almahmeed, W. A. (2014) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.4103/1947-489x.210360
Chapter 13 Hypertension
Kjeldsen, S. E., Aksnes, T. A., Fagard, R. H., & Mancia, G. (2009)
Self-citation
Correlation between Preoperative Pulmonary Artery Pressure and Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
Chockchai, S., Sansanayudh, N., Tasukon, P., Laothavorn, P., Piamsomboon, C., Sanguanwong, S., Naksawadi, C., Uerojanaungkul, P., Tiyanon, W., Pinphanichakarn, V., et al. (2008)
Hemmstoffe des Renin-Angiotensin-Systems
Anlauf, M. (2009) · Springer eBooks · doi:10.1007/978-3-642-01080-4_5
Hypertension in Patients with Concomitant Cardiac Disorders
Tse, H. (2007) · Elsevier eBooks · doi:10.1016/b978-0-323-03961-1.50065-9
Grupo de Trabajo para el manejo de la hipertensión arterial de la Sociedad Europea de Hipertensión (ESH) y la Sociedad Europea de Cardiología (ESC)
Mancia, G., & Fagard, R. H. (2016)
Besondere Bluthochdruckfälle
Derer, W., & Dechend, R. (2014) · Der Kardiologe · doi:10.1007/s12181-014-0596-6
Behandlung von Patienten mit Vorhofflimmern
Ernst, S., & Kück, K. (2006) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-006-0019-8
Predictors of Cardiovascular Outcomes in Patients with Hypertension and Left Ventricular Hypertrophy Emphasis on Isolated Systolic Hypertension and Pulse Pressure
Larstorp, A. C. K. (2012) · NORA - Norwegian Open Research Archives
Илья Клейнер «Портрет Иосифа Бродского» Факторы риска развития фибрилляции предсердий. Современные подходы к лечению
Novikova, N. (2010) · CyberLeninK (CyberLeninka)
Nadciśnienie tętnicze i migotanie przedsionków — profilaktyka
Kjeldsen, S. E., Aksnes, T. A., & Schmieder, R. E. (2009) · Choroby Serca i Naczyń
Self-citation
New Antiarrhythmic Drugs and New Concepts for Old Drugs
Kirchhof, P. F. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2856-5.00112-6
Non-antiarrhythmic Therapies for Cardiac Arrhythmias
DEEDWANIA, P. C., & Lardizabal, J. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0285-9.00084-3
Past and ongoing trials with angiotensin II antagonists
Kjeldsen, S. E. (2006) · CRC Press eBooks · doi:10.1201/b14355-12
Self-citation
Cerebrovascular prevention by angiotensin II receptor antagonists
Volpe, M., & Tocci, G. (2006) · CRC Press eBooks · doi:10.1201/b14355-11
Prevention and Treatment of Atrial Fibrillation in Patients with Hypertension
Kjeldsen, S. E., Aksnes, T. A., Erdine, S. E., & Manolis, A. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-39599-9_9
Self-citation
Relationship between cardiac rhythm disorders, serum urotensin ІІ and angiotensin ІІ levels in patients with stage ii hypertension and carotid atherosclerosis in dynamics of treatment with candesartan and lercanidipine
Візір, В. А., Деміденко, О. В., & Школовий, В. В. (2016) · Zaporozhye Medical Journal · doi:10.14739/2310-1210.2016.5.82546
Europejskie zalecenia dotyczące leczenia nadciśnienia tętniczego: stanowisko Europejskiego Towarzystwa Nadciśnienia Tętniczego 2009
Mancia, G., Laurent, S., Agabiti‐Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cífková, R., Clement, D. L., Coca, A., Dominiczak, A. F., et al. (2010) · Arterial Hypertension
Self-citation
Drug therapy for atrial fibrillation: quo vadis?
Jardine, R. (2017) · SA Heart · doi:10.24170/5-4-2017
Arrhythmias in Cardiomyopathy
Roukoz, H., Adkisson, W. O., Akdemir, B., Krishnan, B., Sakaguchi, S., & Benditt, D. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-44577-9_19
Innovations in Antiarrhythmic Drug Therapy
Kirchhof, P. F., & Fabritz, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-44733-1.00113-9
Atrial Fibrillation
McCaffrey, J. A., & Tracy, C. M. (2017) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.117.005956
Atrial Fibrillation and Hypertension: Two Entities That Usually Coexist
Giannitsi, S., Kallistratos, M. S., Poulimenos, L. E., & Manolis, A. J. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-59918-2_17
Therapie von tachykarden Herzrhythmusstörungen
SCHRICKEL, J. W., & Andrié, R. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-24950-1.00012-3
Guidelines that are just for guidance
Sundaravel, S., Nieves, J., & Baum, S. J. (2018) · Annals of Clinical Hypertension · doi:10.29328/journal.ach.1001009
Pharmacological stroke prevention: RAS inhibitors
Pedersen, O. D., & Torp-Pedersen, C. T. (2012) · doi:10.2217/ebo.12.44
Therapie von Herzrhythmusstörungen
Steven, D., Willems, S., & Meinertz, T. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-22107-1.50086-8
Renin – angiotensin system (RAS) and hypertensive disease"From the link in pathophysiology to the outcomes of inhibition"
AL-Chalabi, A. M. (2009) · Annals of the College of Medicine Mosul/Annals of the College of Medecine · doi:10.33899/mmed.2009.8899
Hypertension and atrial fibrillation: a complex problem requiring one comprehensive solution
Holaj, R. (2019) · Medicína pro praxi · doi:10.36290/med.2019.014
THE USE OF MINERALOCORTICOID RECEPTOR ANTAGONISTS IN THE PRE VENTION OF ATRIAL FIBRILLATION
Ватутин, Н. Т., Shevelok, A. N., Тарадин, Г. Г., & Kravchenko, I. N. (2019) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2019-9-4-260-268
Antiarrhythmic Properties of Non-Antiarrhythmic Drugs in Atrial Fibrillation: Upstream Therapy
Scridon, A., & Martínez‐Rubio, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-34893-9_7
Angiotensin Receptor Blockers
Elliott, W. J., & Black, H. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2766-1.00021-1
New Stroke Prophylaxis Options in Atrial Fibrillation Patients.
Thomas, G., & Lerman, B. B. (2013) · Europe PMC (PubMed Central) · doi:10.4022/jafib.462
Atrial Fibrillation
ZIMETBAUM, P. J., & Falk, R. H. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3358-5.50030-9
Importancia de la prevención de la fibrilación auricular en el paciente hipertenso
Suárez, C. R., Tomás, J. P., Donaire, J. A. G., & de la Morena, J. S. (2007) · Hipertensión · doi:10.1016/s0212-8241(07)72450-7
Kardiovaskuläre Erkrankungen
(2011) · Elsevier eBooks · doi:10.1016/b978-3-437-22702-8.50006-6
Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial?
Kjeldsen, S. E., Narkiewicz, K., Burnier, M., & Oparil, S. (2020) · Blood Pressure · doi:10.1080/08037051.2020.1782595
Self-citation
Covremennye predstavleniya ob ideal'noy kombinatsii antigipertenzivnykh preparatov dlya profilaktiki insul'ta
Ostroumova, O. D., Михайловна, Ф. В., & Guseva, T. F. (2013) · Systemic Hypertension · doi:10.26442/sg28983
The Biomark of Atrial Fibrillation in Patients with Essential Hypertension: Aldosterone
Xu, J., Wang, R., Fu, M.-M., Kuang, D., Shen, L., Wei, Y. Q., Chen, S., Xiao-FengLu, Ding, Y., Zhou, G., et al. (2020) · Journal of Clinical & Experimental Cardiology
Heart Failure as a Consequence of Hypertension
Rader, F., & Victor, R. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-60987-6.00025-9
Place of angiotensin receptor blockers in the treatment of hypertension according to the latest recommendations of the 2013 European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) for the treatment of hypertension
Чукаева, И. И., Solovieva, M. V., & Litvinova, S. N. (2013) · Systemic Hypertension · doi:10.26442/sg28976
ARTICULOS DE REVISION
Serra, J. L. P., & Bendersky, M. (2009)
Industry Pulse
&NA; (2007) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/00151642-200714040-00007
Atrial Fibrillation: Are Associated Risk Factors Surrogates for an Inflammatory State?
Samuels, C. D. (2021) · Journal of Cardiology and Cardiovascular Research · doi:10.37191/mapsci-jccr-2(2)-032
The significance of different biomarkers in the prediction of the development of atrial fibrillation after cardiac surgery
Sudavičienė, D. (2014)
VARIABILITY OF BLOOD PRESSURE IN COMORBIDITY OF ARTERIAL HYPERTENSION AND ATRIAL FIBRILLATION
Боев, С. С., Dotsenko, N. Y., Shekhunova, I. A., Herasymenko, L. V., Yatsenko, O. V., & Lyubitov, D. Y. (2021) · Journal of the Grodno State Medical University · doi:10.25298/2221-8785-2021-19-5-481-488
Hemmstoffe des Renin-Angiotensin-Systems
Weber, F., & Anlauf, M. (2021) · Springer eBooks · doi:10.1007/978-3-662-63825-5_7
Hemmstoffe des Renin-Angiotensin-Systems
Weber, F., & Anlauf, M. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_6
Hemmstoffe des Renin-Angiotensin-Systems
Weber, F., & Anlauf, M. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_8
Hemmstoffe des Renin-Angiotensin-Systems
Weber, F., & Anlauf, M. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_9
Hemmstoffe des Renin- Angiotensin-Systems
Anlauf, M., & Weber, F. (2014) · Springer eBooks · doi:10.1007/978-3-662-43487-1_5
Hemmstoffe des Renin-Angiotensin-Systems
Anlauf, M., & Weber, F. (2013) · Springer eBooks · doi:10.1007/978-3-642-37124-0_5
Hemmstoffe des Renin-Angiotensin-Systems
Anlauf, M. (2012) · Springer eBooks · doi:10.1007/978-3-642-29242-2_5
ACE-Hemmer und Angiotensinrezeptorantagonisten
Anlauf, M. (2008) · Springer eBooks · doi:10.1007/978-3-540-72548-0_5
ACE-Hemmer und Angiotensinrezeptorantagonisten
Anlauf, M. (2006) · Springer eBooks · doi:10.1007/3-540-30505-x_5
ACE-Hemmer und Angiotensinrezeptorantagonisten
Anlauf, M. (2007) · Springer eBooks · doi:10.1007/978-3-540-34370-7_5
Atrial Fibrillation
Sheahan, R. G., & Runge, M. S. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4417-8.50044-9
Reply
Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.036
Self-citation
Hypertension
Weber, M. A. (2009) · Elsevier eBooks · doi:10.1016/b978-0-323-05674-8.50085-2
Hypertension
Gunasekera, M., Bisognano, J. D., & Beck, G. R. (2011) · Springer eBooks · doi:10.1007/978-0-85729-944-4_6
Hemmstoffe des Renin-Angiotensin-Systems
Anlauf, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-21992-4_5
Hemmstoffe des Renin-Angiotensin-Systems
Anlauf, M. (2010) · Springer eBooks · doi:10.1007/978-3-642-13380-0_5

Authors: Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., Nieminen, M. S., & Devereux, R. B.
Affiliations: Cornell University (US)
Helsinki University Hospital (FI)
Haukeland University Hospital (NO)
Glostrup Hospital (DK)
Sahlgrenska University Hospital (SE)
University of Michigan (US)
Oslo University Hospital (NO)
University Hospital of Umeå (SE)
Corresponding author: Wachtell, Kristian
ORCID: Wachtell, Kristian
Lehto, Mika
Gerdts, Eva
Olsen, Michael H.
Hornestam, Björn
Kjeldsen, Sverre E.
Lindholm, Lars H.
Nieminen, Markku S.
Devereux, Richard B.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2005-03
Volume: 45
Issue: 5
Pages: 712-719
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2004.10.068
OpenAlex: W2147918774
Cited by: 826
References: 27
Citations by year: 2026: 9 · 2025: 18 · 2024: 16 · 2023: 17 · 2022: 13 · 2021: 20 · 2020: 20 · 2019: 16 · 2018: 30 · 2017: 32 · 2016: 31 · 2015: 29 · 2014: 36 · 2013: 40 · 2012: 33
FWCI: 64.95
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3096 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Funders: Rigshospitalet
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords: angiotensin II receptor blockade, losartan, atenolol, beta-blockers, stroke prevention, hypertension, left ventricular hypertrophy, antihypertensive therapy, heart failure hospitalization, cardiovascular events, life studies, sinus rhythm maintenance, RAS inhibition, renin-angiotensin system
MeSH terms: Adrenergic beta-Antagonists, Aged, Aged, 80 and over, Atenolol, Atrial Fibrillation, Cause of Death, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Prospective Studies, Risk Factors, Survival Rate, Hypertrophy, Left Ventricular, Losartan, Stroke, Angiotensin II Type 1 Receptor Blockers, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks